Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 5Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Recurrence 1Papillomavirus Infections 1Lymphoma 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × Loperamide × Clear all
NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
11 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡